Oral Session

Oral Session 2-13B MDS：Clinical (1)

Sat. Oct 12, 2019 10:10 AM - 11:10 AM No.13 (Tokyo International Forum, 6F G602)

Chair: Akira Matsuda (Department of Hemato-Oncology, International Medical Center, Saitama Medical University)

+Add all to schedule

[OS2-13B-1] An immune signature-based scoring system to predict the prognosis of MDS patients

Yu-Hung Wang¹, Wen-Chien Lin², Chia-Lang Hsu³, Hsin-An Hou¹, Wen-Chien Chou², Hwei-Fang Tien¹ (1.Hematology, National Taiwan University Hospital, Taipei, N/A = Not Applicable, Taiwan, 2.Laboratory Medicine, National Taiwan University Hospital, Taipei, N/A = Not Applicable, Taiwan, 3.Medical Research, National Taiwan University Hospital, Taipei, N/A = Not Applicable, Taiwan)

[OS2-13B-2] Clinical features and cytogenetic aberrations in A-bomb induced MDS with complex karyotype

Makiko Horai¹, Shinya Sato¹, Masatoshi Matsuo², Masako Iwanaga³, Kensuke Horio⁴, Tatsuro Jo⁴, Yumi Takasaki⁵, Yasuhisa Kawaguchi², Hideki Tsushima², Shinichiro Yoshida⁶, Masataka Taguchi¹, Koji Ando¹, Yasushi Sawayama¹, Yoshitaka Imaizumi¹, Tomoko Hata¹, Yukiyoshi Moriuchi⁷, Yasushi Miyazaki¹ (1.Haematology, Nagasaki University Hospital, Nagasaki, japan, 2.Hematology Nagasaki Harbor Medical Center, Nagasaki, Japan, 3.Department of Frontier Life Sciences, Nagasaki University, Nagasaki, Japan, 4.Hematology, Japanese Red Cross Nagasakai Genbaku Hospital, Nagasaki, Japan, 5.Saint Francis Hospital, Nagasaki, Japan, 6.Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan, 7.Hematology, Sasebo City General Center, Sasebo, Japan)

[OS2-13B-3] Evaluation of Wilms tumor gene 1 expression levels and prognosis of myelodysplastic syndromes

Kiyomi Mashima, Hirotomo Nakashima, Takashi Ikeda, Shinichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shinichi Ochi, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yuko Ishihara, Yasufumi Kawasaki, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Shinichiro Fujiwara, Ken Ohmine, Yoshinobu Kanda (Hematol., Jichi Medical University, Tochigi, Japan)

[OS2-13B-4] Is MDS really treatable?: an experience from Pakistan

Naveena Fatima, Nida Anwar, Aisha Arshad, Sumaira Sharif, Tahir Shamsi (NATIONAL INSTITUTE OF BLOOD DISEASE AND BONE MARROW TRANSPLANTATION, KARACHI, Sindh, Islamic Republic of Pakistan)

[OS2-13B-5] Regulatory T cells and natural killer cells in myelodysplastic syndrome survivors

Fumihito Tajima¹, Koji Adachi¹, Junji Suzumiya² (1.Hematol./Oncol., Yonago Med. Ctr., Tottori, Japan, 2.Oncol./Hematol., Shimane Univ., Shimane, Japan)

[OS2-13B-6] The peroxidase positivity of blasts relates with the response to azacitidine for higher-risk MDS

Tomoko Hata¹, Eo Totriyama², Yuji Kobayashi³, Machiko Fujioka⁴, Miki Hashimoto⁴, Hikaru Sakamoto⁴, Masataka Taguchi⁴, Makiko Horai⁴, Shinya Sato⁴, Koji Ando¹, Yasushi Sawayama⁴, Yoshitaka Imaizumi⁴, Shinichiro Yoshida³, Yukiyoshi Moriuchi², Yasushi Miyazaki¹ (1.Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan, 2.Department of Hematology, Sasebo City General Hospital, Sasebo, Japan, 3.Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan, 4.Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan)